Dog Cancer: Types, Symptoms, Diagnosis, and Treatment Guide
This article is reviewed for clinical accuracy. Always consult your veterinarian for diagnosis and treatment.
Key Takeaways
- Cancer is the leading cause of death in dogs over 10 years of age in the United States, accounting for approximately 47 percent of deaths in dogs older than 10 years according to data from the Morris Animal Foundation Golden Retriever Lifetime Study and related epidemiological research; approximately 1 in 4 dogs will develop cancer at some point in their life, and the incidence increases significantly with age; certain breeds (Golden Retrievers, Bernese Mountain Dogs, Boxers, Rottweilers, Scottish Terriers) have dramatically higher lifetime cancer rates than the general dog population, with Golden Retrievers estimated to develop cancer at rates exceeding 60 percent over their lifetime.
- Mast cell tumor (MCT) is the most common skin tumor in dogs and one of the most common overall; it arises from mast cells (immune cells that store histamine and heparin in cytoplasmic granules); grading determines behavior: the Patnaik 3-tier system (Grade I, II, III) has been partly replaced by the Kiupel 2-tier system (low-grade vs. high-grade) which better predicts metastatic potential; high-grade MCTs have a median survival of less than 4 months without treatment; c-KIT mutations (activating mutations in the KIT receptor tyrosine kinase gene, most commonly exon 11 internal tandem duplications) are present in approximately 15 to 40 percent of MCTs and predict response to targeted therapy with toceranib phosphate (Palladia) or masitinib (Kinavet).
- Lymphoma (lymphosarcoma) is one of the most common cancers in dogs overall; multicentric lymphoma (simultaneous involvement of multiple lymph node chains) is the most frequent form; the WHO clinical staging system uses Roman numerals I through V; the standard of care chemotherapy protocol is CHOP (cyclophosphamide, doxorubicin/hydroxydaunorubicin, vincristine/Oncovin, prednisone) given as a 25-week rotating protocol; first remission rates exceed 80 to 90 percent with CHOP; median first remission duration is approximately 6 to 8 months; dogs with B-cell lymphoma have significantly better prognosis than those with T-cell lymphoma (median survival approximately 12 months vs. 6 months with CHOP).
- Osteosarcoma (OSA) is the most common primary bone tumor in dogs, accounting for approximately 85 percent of all primary bone tumors; it predominantly affects the appendicular skeleton (limbs) at the metaphysis of long bones, particularly the distal radius, proximal humerus, distal femur, and proximal tibia; giant and large breeds (Irish Wolfhounds, Great Danes, Rottweilers, Saint Bernards, Greyhounds) are predisposed; a markedly elevated serum ALP (alkaline phosphatase) in a lame large-breed dog with a lytic/proliferative bone lesion on radiographs is a classic presentation; bone biopsy confirms diagnosis; the standard of care is limb amputation followed by adjuvant carboplatin or cisplatin chemotherapy; median survival with amputation plus chemotherapy is approximately 10 to 12 months, with 20 percent of dogs surviving 2 years.
- Hemangiosarcoma (HSA) of the spleen is a common, highly aggressive malignancy in dogs; it arises from vascular endothelial cells and forms blood-filled cavities within the spleen that can rupture acutely, causing life-threatening hemoabdomen (internal hemorrhage into the abdominal cavity); German Shepherds, Golden Retrievers, and Labrador Retrievers are predisposed; the classic presentation is acute collapse, pale mucous membranes, rapid weak pulse, and distended abdomen from internal bleeding; emergency splenectomy is required to control hemorrhage; even with surgery plus doxorubicin-based chemotherapy, median survival is only 4 to 6 months because microscopic metastases are present at the time of diagnosis in most dogs; unlike benign splenic hematomas, no imaging modality reliably distinguishes splenic HSA from benign nodular disease before surgery.
- The fundamental difference between cytology (fine needle aspirate, FNA) and histopathology (biopsy with tissue section) is critical for cancer diagnosis: FNA collects individual cells for microscopic examination and is fast, minimally invasive, and useful for initial screening of masses (excellent for lymphoma, MCT, and round cell tumors that exfoliate well), but it cannot assess tissue architecture, invasion depth, or surgical margin status; histopathology provides a tissue core or excision, allowing assessment of tissue architecture, mitotic index, vascular invasion, margin evaluation, and definitive grading; for most solid tumors (especially sarcomas, carcinomas, and soft tissue sarcomas), histopathology is required for definitive diagnosis and accurate grading that determines treatment planning; “pre-surgical FNA showed a lipoma” and “post-surgical histopath showed a low-grade sarcoma” is a real scenario that occurs when FNA is incorrectly relied upon as the sole diagnostic step for subcutaneous masses.
The 9-year-old Golden Retriever had a visible lump behind her right front leg, just at the elbow. She had been otherwise normal, eating well, full of energy. The owner had noticed the lump six weeks earlier and was watching it. It had grown. A fine needle aspirate at the veterinary office produced a slide full of round cells with large purple granules filling the cytoplasm: classic mast cell tumor. The next question, the one that determines everything, was what grade. A complete excision was performed with 3-centimeter lateral margins and one fascial plane deep. The Kiupel grading came back high-grade. Regional lymph node aspiration found metastatic MCT in the axillary node. Complete staging workup: thoracic radiographs (3 views), abdominal ultrasound with splenic aspirate. What started as a watch-and-wait lump was now a Stage III mast cell tumor in a breed with the highest cancer burden of any dog. Everything that happened next depended on understanding what this disease actually is.
How Cancer Develops in Dogs
Cancer is not one disease; it is a broad category of diseases defined by uncontrolled cell proliferation resulting from accumulated mutations in genes that regulate cell division (proto-oncogenes, which when mutated become oncogenes), programmed cell death (tumor suppressor genes such as p53 and RB), DNA repair, and cellular differentiation. In dogs, as in humans, cancer arises from a multi-step process of clonal expansion: a single cell acquires a growth advantage through a mutation, replicates, and descendant cells acquire additional mutations that progressively increase autonomy from normal growth controls, allow evasion of immune surveillance, stimulate new blood vessel formation (angiogenesis), and eventually enable invasion of adjacent tissues and metastasis through blood and lymphatic vessels to distant organs. Environmental exposures (tobacco smoke, UV radiation, certain herbicides, asbestos), chronic inflammation (chronic cystitis and transitional cell carcinoma, chronic nasal inflammation and nasal tumors), and heritable genetic predispositions all increase cancer risk. The dramatically higher cancer rates in certain breeds reflect both founder population effects (reduced genetic diversity amplifying the prevalence of cancer-predisposing alleles) and selected breeding traits that inadvertently co-selected cancer-risk genes; the extreme example is the Bernese Mountain Dog, in which histiocytic sarcoma (a dendritic cell malignancy) is so common it is called the “Berner disease.”
Common Cancer Types in Dogs
Mast Cell Tumor (MCT)
Mast cell tumors arise from mast cells in the skin and subcutaneous tissue and represent the most common canine skin tumor, accounting for approximately 16 to 21 percent of all canine skin tumors. They can appear as any type of skin lesion: firm nodule, soft fluctuant mass, raised erythematous plaque, or ulcerated lesion. They may enlarge and shrink spontaneously due to histamine release (Darier’s sign: stroking the mass causes local redness and wheal formation from mast cell degranulation). Diagnosis is made by FNA (mast cells with their characteristic purple cytoplasmic granules are easily identified on cytology), making MCT one of the few tumors where FNA is diagnostically reliable. Complete surgical excision with wide margins (2 to 3 cm lateral, one fascial plane deep for low-grade; up to 3 cm or more for high-grade) is the primary treatment. The Kiupel 2-tier grading system (low-grade vs. high-grade based on mitotic count, multinucleate giant cells, bizarre nuclei, and karyomegaly) predicts behavior more reliably than the older Patnaik 3-tier system (Grade I/II/III): low-grade MCTs have excellent prognosis with complete excision (less than 10 percent recurrence, less than 5 percent metastasis); high-grade MCTs have aggressive behavior with rapid metastasis to regional lymph nodes, spleen, liver, and bone marrow. c-KIT mutation testing (PCR for exon 11 internal tandem duplications, which represent approximately 70 to 80 percent of activating KIT mutations) identifies patients likely to respond to toceranib phosphate (Palladia, 3.25 mg/kg every other day, the first canine-specific FDA-approved cancer drug) or masitinib (Kinavet, 12.5 mg/kg/day). Prednisolone reduces tumor size and provides palliation. Vinblastine plus prednisolone or CCNU (lomustine) plus prednisolone are systemic chemotherapy protocols for high-grade or systemic MCT.
Lymphoma
Canine lymphoma arises from malignant transformation of lymphocytes and is classified by anatomical location (multicentric involving peripheral lymph nodes in 80 to 85 percent of cases, alimentary/gastrointestinal, mediastinal, and cutaneous) and by immunophenotype (B-cell vs. T-cell; B-cell accounts for approximately 70 to 75 percent and has significantly better prognosis). WHO clinical staging (Stage I: single lymph node; Stage II: regional lymph nodes; Stage III: generalized lymphadenopathy; Stage IV: involvement of liver or spleen; Stage V: bone marrow or blood involvement) guides prognosis and treatment. Substage a (no clinical signs) has better prognosis than substage b (clinical signs present). Diagnosis is confirmed by FNA or biopsy of an enlarged lymph node with PARR (PCR for antigen receptor rearrangement) testing to distinguish B-cell from T-cell origin and confirm clonality. The CHOP protocol remains the standard of care: cyclophosphamide (200 to 250 mg/m2 IV or orally every 3 weeks), doxorubicin (30 mg/m2 IV every 3 weeks), vincristine (0.5 to 0.7 mg/m2 IV weekly for the first 4 weeks), and prednisone (2 mg/kg/day tapered over the first 4 weeks), delivered as a rotating 25-week schedule. Dogs achieving complete remission (CR) have the longest survival times; dogs not achieving CR are candidates for rescue protocols (MOPP, LOPP, lomustine/CCNU-based, rabacfosadine/Tanovea-CA1 for B-cell relapse).
Osteosarcoma (OSA)
Osteosarcoma is the most common primary bone tumor in dogs and is a highly aggressive malignancy arising from primitive bone-forming mesenchymal cells. It occurs predominantly in the metaphysis of long bones: distal radius (most common), proximal humerus, distal femur, proximal tibia, and proximal radius. A classical presentation is a large-breed or giant-breed dog with sudden onset severe forelimb lameness, marked soft tissue swelling over the distal radius, and pain on palpation. Radiographs classically show a mixed lytic-proliferative lesion at the metaphysis with periosteal new bone formation (sunburst pattern or Codman’s triangle). Markedly elevated serum ALP (alkaline phosphatase) is a strong prognostic marker: elevated ALP at diagnosis is associated with significantly shorter survival times (median approximately 5 to 6 months vs. 10 to 12 months for dogs with normal ALP) and is thought to reflect high tumor bone turnover. Bone biopsy (Jamshidi needle biopsy under fluoroscopic guidance) confirms histological diagnosis, though a combination of signalment, radiographic appearance, and ALP can be diagnostic enough to proceed directly to treatment in classic cases. Thoracic radiographs (3 views) screen for pulmonary metastases; approximately 15 percent of dogs have visible pulmonary metastases at diagnosis, but greater than 90 percent have micrometastases. Standard of care is limb amputation followed by adjuvant carboplatin (300 mg/m2 IV every 3 weeks for 4 to 6 cycles) or cisplatin (70 mg/m2 IV every 3 weeks); doxorubicin is used in alternating protocols (carboplatin alternating with doxorubicin). Limb-sparing surgery (wide resection with cortical allograft or endoprosthesis) preserves the limb but has equivalent survival to amputation and carries high complication rates (infection, implant failure); it is an option for dogs that are not amputation candidates due to concurrent orthopedic disease or very large body mass. Palliative radiation therapy (3 to 4 large fractions of 8 Gy) provides meaningful pain control (70 to 80 percent response rate) for non-surgical candidates.
Hemangiosarcoma (HSA)
Hemangiosarcoma is an aggressive malignancy of vascular endothelial cells that forms blood-filled vascular spaces within organs. Three primary forms exist in dogs: splenic HSA (most common), right atrial/cardiac HSA (second most common, causes pericardial effusion and cardiac tamponade), and subcutaneous/dermal HSA (best prognosis of the three forms). Splenic and cardiac HSA share a peracute presentation: the vascular spaces within the tumor rupture, causing acute internal hemorrhage (hemoabdomen from splenic rupture, hemopericardium from cardiac tumor) and hypovolemic shock. Breed predispositions include German Shepherd Dogs, Golden Retrievers, Labrador Retrievers, and Skye Terriers. Diagnosis of visceral HSA is often presumptive at presentation: a Golden Retriever or German Shepherd presenting with peracute collapse, pale gums, and abdominal distension with free abdominal fluid on ultrasound (bloody fluid on abdominocentesis) proceeds directly to emergency splenectomy without awaiting histopathology. Emergency splenectomy controls bleeding and allows histological diagnosis. Cardiac HSA can be identified by echocardiography showing a right atrial or pericardial mass. Chemotherapy with doxorubicin-based protocols (doxorubicin single agent at 30 mg/m2 every 3 weeks for 5 cycles, or VAC protocol: vincristine, doxorubicin, cyclophosphamide) extends median survival from 1 to 2 months with surgery alone to 4 to 6 months; the short survival reflects that microscopic metastases are invariably present at presentation. I’M-DOG (investigational metronomic oral dosing) and toceranib (Palladia) are being evaluated as adjuvant therapies. Pericardiocentesis (percutaneous drainage of pericardial effusion) provides immediate hemodynamic stabilization for cardiac HSA but is palliative only.
Transitional Cell Carcinoma (TCC / Urothelial Carcinoma)
Transitional cell carcinoma (now more precisely termed urothelial carcinoma, UC) is the most common urinary bladder tumor in dogs, arising from the transitional epithelium of the bladder wall, typically at the trigone (the base of the bladder where the ureters enter and the urethra exits). This trigone location makes complete surgical excision very difficult or impossible without ureteral reimplantation. Scottish Terriers have a dramatically elevated risk (18 to 20 times the general population risk); Shetland Sheepdogs, Beagles, West Highland White Terriers, and Wire Fox Terriers are also predisposed. Herbicide exposure (particularly organophosphate insecticides and some lawn chemicals) is the strongest identified environmental risk factor in Scottish Terriers. Clinical signs include hematuria, stranguria (straining to urinate), pollakiuria, and sometimes signs of urethral obstruction. Urine cytology has limited sensitivity; the CADET BRAF mutation test (a urine-based PCR test for the BRAF V595E mutation, present in approximately 87 percent of canine urothelial carcinomas) is a highly sensitive and non-invasive diagnostic test. Cystoscopic biopsy or traumatic catheter biopsy provides histological confirmation. Medical management with piroxicam (NSAID; 0.3 mg/kg/day; has direct anti-tumor activity through COX-2 inhibition and induces apoptosis in UC cells, with a reported 20 percent response rate as monotherapy) alone or combined with mitoxantrone (5 mg/m2 IV every 3 weeks), carboplatin, or vinblastine provides palliative tumor control; median survival with piroxicam plus chemotherapy is approximately 6 to 12 months. Novel tyrosine kinase inhibitors (toceranib, enrolment in clinical trials) are being evaluated.
Oral Melanoma
Oral malignant melanoma is the most common oral tumor in dogs, arising from melanocytes in the gingiva, tongue, lip, or hard palate. It is highly locally invasive (invading bone) and has a high rate of metastasis to regional lymph nodes (55 to 74 percent at diagnosis) and lungs. Staging by radiography and CT of the primary site, regional lymph nodes (mandibular, medial retropharyngeal), and thorax is essential. Treatment of the primary tumor is wide surgical excision (mandibulectomy or maxillectomy); radiation therapy achieves local control rates of 60 to 70 percent. The USDA-licensed Oncept canine melanoma vaccine (a xenogeneic DNA vaccine encoding human tyrosinase, a melanocyte differentiation antigen) is the first licensed veterinary cancer vaccine; it is given as a series of 4 intradermal injections at 2-week intervals, then every 6 months; clinical studies show a significant survival benefit in Stage II/III oral melanoma when combined with local therapy, with median survival times of approximately 389 days compared to historical controls of approximately 90 to 150 days with surgery alone.
Diagnosing Cancer: Cytology vs. Histopathology vs. Imaging
| Diagnostic Tool | What It Provides | Best For | Limitations |
|---|---|---|---|
| Fine needle aspirate (FNA) cytology | Individual cells on a slide; rapid, minimally invasive, inexpensive ($30 to $100 plus lab fee) | Lymphoma, MCT, round cell tumors, initial triage of any accessible mass | Cannot assess tissue architecture, invasion, or mitotic index; cannot grade most sarcomas or carcinomas; false negatives from non-exfoliating tumors (sarcomas) |
| Core needle biopsy (Tru-Cut) | Tissue core preserving architecture; can be done under ultrasound guidance; outpatient | Liver, spleen, soft tissue masses; pre-surgical diagnosis; grading of soft tissue sarcomas | Smaller sample than incisional biopsy; needle tract can seed tumor cells along the biopsy track if not planned carefully |
| Incisional biopsy (wedge biopsy) | Larger tissue sample; preserves architecture; definitive grading | Large masses where excision is not yet planned; bone tumors (Jamshidi needle for OSA) | Requires sedation or anesthesia; wound management; must plan biopsy tract to be excised with the definitive surgery |
| Excisional biopsy | Complete removal plus histopathology; simultaneous treatment and diagnosis | Smaller accessible masses (<2 cm); masses where clean margins are expected (skin tumors in non-constrained locations) | If margins are incomplete on histopath, second surgery or radiation is needed; not appropriate for masses likely to require wide excision |
| Thoracic radiographs (3 views) | Screening for pulmonary metastases; cardiac silhouette; pleural effusion | Staging for any malignancy with pulmonary metastatic potential; baseline before surgery | Cannot detect metastases <7 to 8 mm; CT is more sensitive for pulmonary nodule detection |
| Abdominal ultrasound | Evaluation of liver, spleen, lymph nodes, kidneys, adrenals, bladder; free fluid detection; guided aspirates | Staging for lymphoma, HSA, MCT, carcinomas; free fluid evaluation in collapse patient | Operator dependent; cannot reliably distinguish HSA from hematoma; CT more sensitive for small lesions |
| CT scan | 3D anatomical detail; superior sensitivity for pulmonary nodules, bone invasion, lymph node size; vascular mapping for surgical planning | Pre-surgical planning for OSA, oral tumors, nasal tumors; pulmonary staging; brain tumors | Requires general anesthesia in most dogs; higher cost ($1,000 to $2,500); limited availability outside specialty centers |
| PARR (PCR for antigen receptor rearrangement) | Determines B-cell vs. T-cell immunophenotype; confirms clonality (distinguishing lymphoma from reactive lymphadenopathy) | Lymphoma immunophenotyping when flow cytometry is not available; ambiguous cytology | Not 100% sensitive; false negatives in approximately 10 to 15 percent; PCR-based, so tissue quality matters |
| CADET BRAF urine test | Detects BRAF V595E mutation in shed urothelial cells in urine; non-invasive | Screening and diagnosis of transitional cell carcinoma/urothelial carcinoma; monitoring for recurrence | Specific to BRAF-mutant UC (~87% of cases); does not detect non-BRAF-mutant UC; not a grading tool |
Warning Signs of Cancer in Dogs
The American Veterinary Medical Association (AVMA) publishes a list of common cancer warning signs in dogs. Any of the following should prompt a veterinary evaluation:
- Abnormal swellings that persist or continue to grow
- Sores that do not heal (non-healing wounds can indicate locally invasive tumors)
- Weight loss without a clear dietary explanation
- Loss of appetite
- Bleeding or discharge from any body opening
- Offensive odor from the mouth, ears, or body surface
- Difficulty eating or swallowing
- Reluctance to exercise or loss of stamina
- Persistent lameness or stiffness
- Difficulty breathing, urinating, or defecating
The practical addition to this list for high-risk breeds (Golden Retrievers, Bernese Mountain Dogs, Boxers, Rottweilers): a palpable lump anywhere on the body in a dog over 7 years of age should be aspirated at the next veterinary visit rather than monitored at home. The “wait and see if it grows” approach is appropriate only for clearly benign lesions (soft, freely movable subcutaneous lipomas confirmed by FNA); any firm, fixed, rapidly growing, or previously aspirated-and-not-confirmed-benign mass warrants timely evaluation.
Treatment Approaches for Cancer in Dogs
| Modality | Mechanism | Best Suited For | Notes |
|---|---|---|---|
| Surgery | Physical removal of tumor with margins | Solid tumors amenable to excision with adequate margins: MCT, soft tissue sarcoma, OSA (amputation), oral tumors, splenic HSA | Goal is complete excision with clean histologic margins; incomplete excision requires radiation or re-excision for local control |
| Chemotherapy (systemic) | Cytotoxic drugs target rapidly dividing cells | Lymphoma (CHOP), disseminated/systemic disease, post-surgical adjuvant therapy (OSA: carboplatin), MCT (vinblastine + prednisone, CCNU) | Dogs tolerate chemotherapy better than humans (less nausea/hair loss); goal is quality of life, not always cure; CBC monitoring for myelosuppression required |
| Radiation therapy | Ionizing radiation damages DNA in tumor cells | Brain tumors, nasal tumors, oral tumors with incomplete margins, OSA palliation, mast cell tumors in non-surgically accessible locations | Requires repeated anesthesia (typically 15 to 20 daily fractions for definitive RT, or 3 to 5 large fractions for palliation); available at university referral centers and specialty oncology practices |
| Targeted therapy (tyrosine kinase inhibitors) | Inhibits specific oncogenic signaling pathways (KIT, VEGFR, PDGFR) | c-KIT mutant MCT: toceranib (Palladia), masitinib (Kinavet); TCC/urothelial carcinoma: toceranib; thyroid carcinoma: toceranib | Toceranib: 3.25 mg/kg PO every other day; common side effects: GI toxicity, protein-losing nephropathy, neutropenia; monitor urinalysis and CBC |
| Immunotherapy/vaccine | Stimulates immune recognition of tumor antigens | Oral malignant melanoma (Stage II/III): Oncept canine melanoma vaccine (USDA licensed) | 4-dose induction series (2-week intervals) then every 6 months; adjunct to local therapy (surgery, radiation); not a standalone treatment |
| Metronomic chemotherapy | Low-dose continuous chemotherapy targets tumor vasculature and regulatory T cells | Adjuvant post-surgical therapy for soft tissue sarcoma; TCC maintenance; palliation for various tumors | Common protocols: oral cyclophosphamide 12.5 to 15 mg/m2/day + piroxicam 0.3 mg/kg/day; less myelosuppressive than full-dose protocols; lower cost |
| NSAIDs (piroxicam) | COX-2 inhibition; direct apoptosis induction in COX-2 expressing tumors | Transitional cell carcinoma/urothelial carcinoma (as monotherapy or with mitoxantrone/carboplatin); oral melanoma; rectal tumors | 20 percent objective response rate in TCC as monotherapy; must monitor renal function; avoid concurrent nephrotoxic drugs |
| Palliative/hospice care | Pain management, quality of life maintenance | Dogs where curative treatment is not elected or available; end-stage disease | NSAIDs, gabapentin, tramadol, amantadine for pain; prednisolone for lymphoma palliation (4 to 8 weeks response); hospice-level care discussion with owner |
Age-Specific Considerations
Young Dogs (Under 5 Years)
- Cancer is uncommon in young dogs but does occur; the most important cancer to know about in young dogs is histiocytic sarcoma in Bernese Mountain Dogs, which can occur even before 5 years and carries a dismal prognosis; transmissible venereal tumor (TVT), which is a naturally occurring, sexually transmitted allograft tumor, occurs in intact young dogs and is highly responsive to single-agent vincristine chemotherapy; bone tumors and lymphoma, though more common in middle-aged and senior dogs, can appear in young large breeds; any mass in a young dog warrants FNA rather than assumption of benignity
- Histiocytoma is a common benign skin tumor of young dogs (typically under 3 years) that appears as a red raised “button” on the head, ears, or limbs and often regresses spontaneously within 3 months; it can look alarming but is benign; FNA confirms the characteristic histiocyte cytology; watchful waiting is appropriate for typical presentations in young dogs; if the mass does not regress within 2 to 3 months or the dog is older, surgical excision and histopathology are warranted
Middle-Aged Dogs (5 to 9 Years)
- Middle age is when breed-specific cancer risk becomes clinically significant; Golden Retrievers, Rottweilers, Boxers, and Bernese Mountain Dogs should have thorough physical examination with careful palpation of all peripheral lymph nodes and inspection of oral cavity at every wellness visit from age 5 onward; Boxers are predisposed to MCT, brain tumors (gliomas), lymphoma, and thyroid carcinoma; Rottweilers have markedly elevated osteosarcoma and lymphoma risk
- Transitional cell carcinoma in Scottish Terriers peaks at 9 to 11 years but can appear at 6 to 7 years; any Scottish Terrier with urinary signs (hematuria, stranguria) should have a CADET BRAF urine test at the first presentation rather than empirically treating with antibiotics for presumed UTI
- Splenic masses detected on imaging in middle-aged large breeds: the old “one-third rule” (one-third of splenic masses are HSA, one-third are hematoma/nodular hyperplasia, one-third are other) has been revised by more recent data from university hospitals showing approximately 50 to 70 percent of resected splenic masses in large breed dogs are malignant; elective splenectomy for any splenic mass greater than 5 cm in a large-breed dog is the recommendation of most veterinary oncologists regardless of whether the dog is symptomatic
Senior Dogs (10 Years and Older)
- Cancer is the leading cause of death in dogs over 10 years; at this age, the question for any new mass is not “is this likely cancer?” but rather “what type, what grade, and what is the right treatment given this dog’s overall health and expected lifespan?” Senior dogs tolerate surgery and even chemotherapy well if their organ function (renal, hepatic, cardiac) is adequate; age alone is not a contraindication to cancer treatment; quality of life assessment should drive treatment decisions, not calendar age
- Oral melanoma peaks in dogs over 10 years; dark-pigmented breeds (Cocker Spaniels, Chow Chows, Scottish Terriers, Labrador Retrievers) are most at risk; routine oral examination at every wellness visit including lifting the lip to examine the gingiva, buccal mucosa, and tongue base is important for early detection; early-stage oral melanoma (Stage I, primary tumor less than 2 cm, no lymph node metastasis) treated with surgery has 2-year survival rates of approximately 20 to 30 percent; later stages have significantly worse outcomes
- Prednisone-only palliative therapy for lymphoma in senior dogs with concurrent significant disease (renal insufficiency, cardiac disease, hepatic disease) can provide 4 to 8 weeks of good quality life with minimal monitoring burden; this is a valid and compassionate option when CHOP chemotherapy is not feasible or the owner chooses a less intensive approach
US Cost Overview for Cancer Diagnosis and Treatment
| Item | Typical US Cost |
|---|---|
| Fine needle aspirate (office procedure + lab cytology) | $80 to $200 |
| Histopathology (tissue biopsy) | $150 to $350 (lab fee; plus procedure cost) |
| CADET BRAF urine test (TCC/UC) | $150 to $200 |
| CT scan (staging or surgical planning) | $1,000 to $2,500 |
| CHOP lymphoma chemotherapy (full 25-week protocol) | $5,000 to $10,000 |
| Carboplatin (per dose, for OSA adjuvant) | $300 to $700 per treatment (4 to 6 treatments) |
| Toceranib/Palladia (per month) | $300 to $600/month |
| Limb amputation (OSA) | $2,000 to $5,000 |
| Splenectomy (HSA or splenic mass) | $2,000 to $5,000 |
| Mandibulectomy/maxillectomy (oral tumor) | $2,500 to $6,000 |
| Radiation therapy (definitive, 15 to 20 fractions) | $8,000 to $18,000 |
| Radiation therapy (palliative, 3 to 5 fractions for OSA pain) | $2,000 to $5,000 |
| Oncept melanoma vaccine (4-dose induction) | $600 to $1,200 |
Myths and Facts About Dog Cancer
If my dog has cancer, surgery will spread it.
This is one of the most persistent and damaging myths in veterinary oncology, and it causes owners to decline surgical treatment that would have been curative. Properly planned and executed surgery does not spread cancer. The rare exception is a tumor with extremely poor surgical planes where cells are disrupted into the wound or bloodstream; this is managed by using appropriate surgical margins, a “no-touch” technique, and changing gloves between specimen handling and wound closure. Surgically resected mast cell tumors with clean margins are cured in the majority of cases. The scenario where surgery appears to worsen things is usually one of two situations: the tumor was more advanced than recognized before surgery (micrometastases already present), or the original surgical margins were inadequate (incomplete excision), not the surgery itself causing spread.
Chemotherapy makes dogs desperately sick, just like in humans.
Dogs receiving chemotherapy tolerate it substantially better than humans because the dose-intensity priority in veterinary oncology is different. In human oncology, chemotherapy doses are pushed to the maximum tolerable to pursue cure. In veterinary oncology, the goal is to maintain quality of life; doses are calculated to cause minimal side effects rather than to push to the limit. Approximately 75 to 80 percent of dogs receiving CHOP chemotherapy for lymphoma experience minimal to no side effects. Approximately 20 to 25 percent experience mild, transient GI side effects (a day of nausea, reduced appetite, soft stools) that resolve without hospitalization. Fewer than 5 percent experience serious side effects (severe neutropenia requiring hospitalization). Dogs do not lose their hair (except those with continuously growing coats: Poodles, Old English Sheepdogs). Owners are typically surprised by how normal their dog seems during chemotherapy.
A dog with cancer should be fed a raw meat diet to “starve the cancer of sugar.”
The idea that dietary carbohydrate restriction starves cancer is appealing but not supported by veterinary clinical evidence as a treatment modality. Cancer cells do preferentially use glucose through anaerobic glycolysis (the Warburg effect), but so do all rapidly dividing cells, and selectively depriving a tumor while the dog remains adequately nourished is not achievable through diet alone. More practically: raw meat diets carry documented risks of Salmonella, Listeria, E. coli, and Toxoplasma infections, and immunocompromised patients (including those receiving chemotherapy that causes transient neutropenia) are at significantly elevated risk from these pathogens. The most important nutritional goal in a dog with cancer is maintaining body weight and muscle mass (cancer cachexia is a real syndrome that worsens outcomes); a complete, highly digestible diet adequate in protein and calories is far more evidence-based than any specific “anti-cancer diet.” Commercial diets specifically formulated for cancer patients (Hill’s Prescription Diet n/d) incorporate reduced carbohydrate, elevated n-3 fatty acids (fish oil), and elevated arginine based on research by Dr. Gregory Ogilvie; these are reasonable options but are supplements to, not replacements for, standard oncology treatment.
Red Flags: Signs That Mean See a Vet Soon
- Acute collapse, pale gums, and a distended abdomen in a large breed dog (especially German Shepherd, Golden Retriever, or Labrador Retriever over 7 years): this is splenic hemangiosarcoma with hemoabdomen until proven otherwise; emergency evaluation and likely emergency surgery
- Any lump that has doubled in size within 2 to 4 weeks, is firm and fixed to underlying tissue, or is ulcerated and bleeding: do not wait; FNA at the next available appointment
- Sudden severe lameness in a large or giant breed dog with soft tissue swelling over the distal radius or proximal humerus: radiographs to evaluate for osteosarcoma; these dogs are in significant pain and pain management must be addressed immediately
- Generalized peripheral lymphadenopathy (multiple enlarged lymph nodes detectable under the jaw, in front of the shoulders, in the groin, and behind the knees) in a middle-aged or older dog: very suspicious for multicentric lymphoma; FNA of the largest node at the earliest opportunity
- Blood in the urine, straining to urinate, or frequent urination that does not resolve with antibiotic treatment in a Scottish Terrier, Shetland Sheepdog, or Beagle over 7 years: bladder TCC; CADET BRAF urine test or cystoscopy rather than repeated antibiotic courses
- Sudden onset breathing difficulty, muffled heart sounds, or jugular vein distension in a large breed dog: right atrial hemangiosarcoma with pericardial effusion and cardiac tamponade; emergency echocardiography and pericardiocentesis
- Black or dark-pigmented, rapidly growing mass on the gum line or hard palate of any dog: oral melanoma; immediate staging and surgical consultation; delays worsen prognosis at every stage
Frequently Asked Questions About Dog Cancer
What are the most common cancers in dogs?
The most common cancers in dogs by frequency are: mast cell tumor (most common skin tumor), lipoma (most common benign tumor, not malignant), lymphoma (one of the most common overall malignancies), hemangiosarcoma (most common splenic and cardiac malignancy in large breeds), osteosarcoma (most common primary bone tumor), soft tissue sarcoma (a category including fibrosarcoma, peripheral nerve sheath tumor, myxosarcoma), mammary gland carcinoma (most common tumor in intact female dogs), transitional cell carcinoma (most common bladder tumor), and oral melanoma (most common oral tumor). Breed matters enormously: a Golden Retriever’s lifetime cancer risk is estimated above 60 percent; the most common lethal cancer in Golden Retrievers in the Morris Animal Foundation study was hemangiosarcoma.
How long can a dog live with cancer?
Survival time depends entirely on the cancer type, grade, stage, and treatment. Ranges: a low-grade mast cell tumor completely excised with clean margins is effectively cured (greater than 90 percent disease-free at 2 years); lymphoma with CHOP chemotherapy has a median survival of 12 to 14 months for B-cell and 6 months for T-cell; osteosarcoma with amputation plus carboplatin has median survival of 10 to 12 months; splenic hemangiosarcoma with surgery plus doxorubicin has median survival of 4 to 6 months; transitional cell carcinoma with piroxicam plus mitoxantrone has median survival of 6 to 12 months. These are medians; some dogs do much better, some worse. The most important variables beyond the cancer itself are whether treatment is started, what protocol is used, and whether the dog achieves remission or has complete excision.
Should I pursue cancer treatment or focus on quality of life?
This is a deeply personal decision and there is no single right answer. The key reframing: in veterinary oncology, treatment and quality of life are not opposites. Most cancer treatment protocols in dogs are designed to maintain quality of life throughout treatment. A dog receiving CHOP chemotherapy for lymphoma is typically active, eating normally, and enjoying life between treatments. A dog with osteosarcoma after amputation often adapts rapidly and functions well on three legs. The questions to work through with a board-certified veterinary oncologist (DACVIM Oncology) are: what is realistic (cure vs. extension of good-quality life), what does day-to-day treatment look like for this specific cancer, what are the financial and time commitments, and what would your dog tell you if they could. Veterinary hospice and palliative care are also valid paths for dogs where aggressive treatment is not appropriate or not elected.
Can dog cancer be prevented?
There is no proven comprehensive prevention strategy, but several steps reduce specific cancer risks. Spaying female dogs before the first heat dramatically reduces mammary gland carcinoma risk (risk reduction of approximately 99.5 percent when spayed before first heat); this risk benefit must be weighed against increased risks of other conditions (MCT, hemangiosarcoma, and certain orthopedic problems have higher incidence in spayed/neutered large breeds in some studies). Avoiding exposure to known carcinogens (tobacco smoke, certain herbicides, asbestos, excessive UV radiation in light-pigmented dogs) reduces environmental risk. Maintaining a healthy body weight reduces the risk of several cancers. Genetic testing for breed-specific predispositions is available for some conditions but is not yet at the stage where it drives preventive management decisions in most breeds. Annual wellness exams with thorough physical examination allow early detection of accessible masses.
What is a veterinary oncologist and when should I see one?
A veterinary oncologist is a veterinarian who completed a 3-year residency in oncology after veterinary school and passed the board examination of the American College of Veterinary Internal Medicine (Oncology subspecialty), earning the designation DACVIM (Oncology). They have specialized training in cancer diagnosis, chemotherapy administration, radiation therapy planning, and clinical trials. You should see one when your dog receives a cancer diagnosis, when a mass is found that cannot be definitively characterized by FNA, before choosing a treatment protocol for any serious malignancy, and whenever your general practitioner recommends it. University veterinary teaching hospitals and large specialty referral centers have oncology services. A consultation does not obligate you to treatment; it gives you accurate information about what the diagnosis means and what the realistic options are, so you can make an informed decision.
Is a lump on my dog always cancer?
No. The majority of lumps in dogs are benign. The most common lump in adult and older dogs is a lipoma (benign fatty tumor), which feels soft, smooth, freely movable, and grows slowly; it is harmless unless it causes mechanical problems from its size or location. Sebaceous cysts, warts (viral papillomas, especially in young dogs), histiocytomas (in young dogs, self-resolving), and reactive lymph nodes from local infection are other common benign causes. However, malignant tumors also occur as unremarkable lumps, including MCTs, which can look exactly like a harmless cyst. The only reliable way to distinguish a benign lump from a malignant one is FNA cytology or biopsy. “Watch and wait” is only appropriate for lumps that have been aspirated and confirmed benign, not for uncharacterized masses in adult or senior dogs.
What is the difference between a Grade II and Grade III mast cell tumor?
Under the Patnaik grading system: Grade I MCTs are well-differentiated with minimal mitotic activity, confined to the dermis, and carry an excellent prognosis with complete excision; Grade II MCTs (the majority of MCTs) are intermediate, with variable behavior; Grade III MCTs are poorly differentiated with high mitotic index, invade deep into subcutaneous tissue, and carry a poor prognosis with rapid metastasis. The problem is that Grade II MCTs have a very wide range of behaviors, from effectively benign to highly aggressive. The Kiupel 2-tier system (low-grade vs. high-grade) was developed to resolve this ambiguity: it reclassifies Grade II MCTs into low- or high-grade based on specific criteria (mitotic figures per 10 high power fields greater than 7, multinucleate giant cells, bizarre nuclei, karyomegaly) that better predict metastatic potential. Most veterinary pathologists now report both systems; the Kiupel grade is the more actionable for treatment planning.
For more guides on keeping your dog healthy, browse all our Dog Health articles.
Explore Dog Health Articles